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Abstract
Thalidomide has regained value in the multimodality treatment of leprosy, multiple myeloma,
prostate, ovarian and renal cancer. Complications related to arterial and venous complications are
well described. However, pulmonary complications remain relatively uncommon. The most
common pulmonary side-effect reported is non-specific dyspnea. We report a patient with multiple
myeloma, who developed an eosinophilic pneumonia, shortly after starting thalidomide. She had
complete resolution of her symptoms and pulmonary infiltrates on discontinuation of the drug and
treatment with corticosteroids. Physicians should be cognizant of this potential complication in
patients receiving thalidomide who present with dyspnea and pulmonary infiltrates.
Background
A 68 year-old woman, with multiple myeloma, was
admitted with progressive, exertional dyspnea and dry
cough, which started a few days before presentation. With
exercise, her oxygen saturation fell to 85% on room air.
Two weeks prior, she had developed diffuse erythematous
skin lesions that spontaneously resolved. She denied
fever, chills, rigors, night sweats, weight loss, hemoptysis,
myalgias, arthralgias, chest pain, palpitations, orthopnea
and paroxysmal nocturnal dyspnea. She had no sick con-
tacts. Two months before, she began treatment with tha-
lidomide 50 mg daily, which was titrated up to 200 mg
daily over two weeks. She also received dexamethasone 40
mg for four consecutive days every four weeks. Her past
medical history was significant for remote cancers: breast
cancer, for which she underwent lumpectomy and radia-
tion; malignant melanoma, which was resected and
endometrial cancer, for which hysterectomy and pelvic
radiation were performed. There was no previous history
of atopy or asthma. On presentation, her medications
included aspirin, iron, alendronate, calcium, multivita-
min and thalidomide (200 mg daily). She was not on dex-
amethasone at the time of presentation, but had received
her dosing the previous month. She had no drug allergies
and never received trimethoprim-sulfamethoxazole
prophylaxis. She had no pertinent hobbies, pets, travel
history or occupational exposures. Her human immuno-
deficiency virus status was negative.
On physical examination, she was in mild respiratory dis-
tress and on 2 liters of oxygen, her saturation was 96%.
Vital signs and cardiac examination were normal. Respira-
tory examination revealed bibasilar crackles. There were
no skin lesions, lymphadenopathy, joint swelling or ery-
thema.
On admission, her white blood cell count was 5.6 k/uL
(neutrophils 84%, lymphocytes 7.1%, and eosinophils
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3%) and her hemoglobin 10.2 g/dl. Her blood chemis-
tries were normal. Computed tomography pulmonary
angiography (CTPA) of the chest revealed no pulmonary
embolism. There were patchy ground glass infiltrates
bilaterally (Fig 1a). Transthoracic echocardiogram
revealed normal systolic function and pulmonary pres-
sures. Bronchoscopy was performed to obtain a broncho-
alveolar lavage (BAL) specimen and transbronchial
biopsies. Specimens from the right middle lobe were sent
for cell count and differential, bacterial and fungal cul-
tures, acid fast bacilli stains and cytology. There were 18%
lymphocytes and 33% eosinophils on the differential cell
count. There was no evidence of cytomegalovirus, bacte-
ria, fungus or Pneumocystis jiroveci. Transbronchial
biopsy specimens showed evidence of interstitial pneu-
monitis with histiocytic clusters suggestive of granulomas
(Fig 2). There was no evidence of malignancy. No para-
sites were seen. These results supported a diagnosis of
acute eosinophilic pneumonia.
The thalidomide was discontinued and she was started on
prednisone 40 mg orally daily. She was discharged to
home, after three days in the hospital, with minimal dys-
pnea. At that time, she was saturating 98% on room air, at
rest, with no significant desaturation on exercise. Within
one week, she was no longer dyspneic. The patient
remained symptom free after discontinuation of the ster-
oids. Spirometry and diffusion capacity, one month later,
were normal. Repeat CT evaluation showed complete
radiographic resolution of the infiltrates (Fig 3).
Discussion
Thalidomide, originally a sedative-hypnotic drug, has
been shown to have activity in the multimodality treat-
ment of leprosy, hematologic malignancies and solid
tumors, including prostate, ovarian, renal cell cancer and
Kaposi's sarcoma[1,2], due to its antiangiogenic, immu-
nomodulating and anticytokine properties. Angiogenesis,
High-resolution transverse CT image shows extensive patchy  ground-glass opacity throughout both lungs Figure 1
High-resolution transverse CT image shows exten-
sive patchy ground-glass opacity throughout both 
lungs.
The lung pathology consists of a mild interstitial pneumonitis  with scattered clusters of histiocytes within the alveolar  space consistent with loosely-formed granulomas Figure 2
The lung pathology consists of a mild interstitial 
pneumonitis with scattered clusters of histiocytes 
within the alveolar space consistent with loosely-
formed granulomas. (Hematoxylin and eosin, 100×).
High-resolution transverse CT image at the same levels as  figure 1 shows resolution of ground-glass opacity Figure 3
High-resolution transverse CT image at the same 
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downregulation of tumor necrosis factor, interference
with stromal cell/myeloma adhesive properties and stim-
ulation of natural killer cells are thought to be the mech-
anisms by which it exerts its beneficial effects in multiple
myeloma[3].
Serious pulmonary complications due to thalidomide use
are not common. The most common pulmonary side-
effect is non-specific dyspnea, reported in 4% to 54%[4].
This frequently improves on cessation of the drug. Arterial
and venous thromboses, namely, pulmonary embolism
and deep vein thromboses, [5-8] are the most serious pul-
monary complications and their frequency appears to
increase when combined with dexamethasone and other
chemotherapeutic drugs [9]. Interstitial pneumonia has
been described in case reports in patients with ovarian
cancer and multiple myeloma [10-12]. However, none of
these patients had significant eosinophilia in the BAL
fluid. The case series of three patients with advanced pros-
tate cancer who were treated with a combination of
docetaxel and thalidomide, attributed the pulmonary tox-
icity to the primarily the doxacetal, to which severe inter-
stitial pneumonias had been ascribed[12].
A case report in the Japanese literature, describes a patient
with a severe interstitial pneumonia, rash and eosi-
nophilia in the BAL specimen, who required mechanical
ventilation. His pneumonia and rash initially responded
to discontinuation of the thalidomide and a course of
steroids. However, his course was subsequently compli-
cated by methicillin resistant staphylococcus aureus
(MRSA) septicemia and he demised [13]. It is not clear
from the information provided in the case that the eosi-
nophilia was definitely due to the thalidomide and not an
undiagnosed underlying process.
Pleural effusions may occur [14], with the hypersensitiv-
ity-type responses [15]. Hypersensitivity pneumonitis has
been described with an FDA-approved thalidomide ana-
log, lenalidomide[16].
There is one case report of a patient with multiple mye-
loma who developed dyspnea and ground glass infiltrates
on thalidomide. The bronchoalveolar lavage contained
31% neutrophils, 40% lymphocytes, 20% eosinophils
and 1% plasma cells. Transbronchial biopsy specimens
revealed fibroblastic plugs in the alveolar spaces with sur-
rounding interstitial inflammation, diagnostic of organiz-
ing pneumonia[17].
There are published case reports of patients who devel-
oped pulmonary hypertension seemingly due to thalido-
mide. One case reported described a man with multiple
myeloma, who transiently developed severe pulmonary
hypertension on thalidomide, which improved on dis-
continuation and worsened on a rechallenge with the
drug[18]. Another case reports a patient with multiple
myeloma, who had significant dyspnea, was found to
have severe pulmonary hyperstension and subsequently
died. There were no other identifiable causes of her pul-
monary hypertension on pathology and review of her his-
tory and laboratory results[18,19].
To our knowledge, this is the first reported case, in the
English literature, of an acute eosinophilic pneumonia,
related to thalidomide. The degree of eosinophilia in the
BAL fluid, in the absence of any historical, physical or lab-
oratory data to support an alternative cause of eosi-
nophilic pneumonia, strongly supports the diagnosis of
an esoinophilic pneumonia. The absence of eosinophils
on histology would have been supportive of this diagno-
sis, but is not required for the diagnosis of eosinophilic
pneumonia. Her clinical improvement on discontinua-
tion of the thalidomide suggests that the thalidomide was
the most reasonable culprit. This is somewhat con-
founded by the simultaneous treatment with prednisone,
as it can be argued that the patient responded to the ster-
oid, as eosinophilic pneumonias characteristically do and
not necessarily to discontinuation of the drug. Resump-
tion of the thalidomide, with recrudescence of the dysp-
nea and pulmonary infiltrates, would confirm the
diagnosis of thalidomide-induced interstitial pneumonia.
However, this is not recommended.
Conclusion
In conclusion, we present a case of eosinophilic pneumo-
nia secondary to thalidomide. The patient's clinical
course, radiographic and bronchoscopic findings strongly
support a diagnosis of thalidomide-induced eosinophilic
pneumonia, in the absence of any other positive historical
and laboratory evidence. Physicians should be cognizant
of this potential complication in patients receiving thalid-
omide who present with dyspnea and pulmonary infil-
trates.
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